Journal of Nuclear Medicine · 2019 · 69 citations · 17 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyMolecular OncologyChemokine NetworksChemokine SignalingHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyTargeted Cancer TherapyTargeted TherapyChemokine Receptor AntagonismChemokine Receptor Cxcr4 AntagonismChemokine-based TherapyHematopoietic DisordersSafety Profile CharacterizationSerious Adverse EventsTransmembrane ProteinsTransplantation For Hematologic Malignancies
The chemokine receptor CXC-chemokine receptor 4 (CXCR4) is a transmembrane receptor involved in survival, proliferation, and dissemination of different cancers, including hematopoietic malignancies. Relapsed or refractory hematopoietic cancers are frequently resistant to conventional therapy, and novel highly active strategies are urgently needed. CXCR4-directed endoradiotherapy constitutes a highly promising targeted therapeutic concept. Here, we investigated the adverse effects of this novel treatment approach. <b>Methods:</b> Twenty-two patients with heavily pretreated lymphoproliferative or myeloid malignancies were treated with <sup>177</sup>Lu- or <sup>90</sup>Y-pentixather—a CXCR4-directed therapeutic radioligand—before conventional conditioning therapy followed by autologous or allogeneic hematopoietic stem cell transplantation. Twenty-five CXCR4-directed endoradiotherapies were administered to those patients. Adverse events occurring between endoradiotherapy and the start of conventional conditioning therapy were retrospectively analyzed and graded for the estimation of the safety profile. <b>Results:</b> CXCR4-directed endoradiotherapy with pentixather showed a favorable toxicity profile. As expected, the hematopoietic system was most affected, with all subjects developing cytopenias. Except for 1 acute kidney failure, grade 3, due to tumor lysis syndrome, overall nephro- and hepatotoxicity was low. Other higher-grade adverse events were either transient and resolved or easily manageable. <b>Conclusion:</b> Therapy with radiolabeled pentixather appears to be well tolerated and easily applicable when preceding conventional conditioning regimens for hematopoietic stem cell transplantation.
17
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +17
John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 809 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Anna Imhof, Philippe Brunner, Nicolas Marincek et al. · Journal of Clinical Oncology · 2011 · 621 citations
Medicine, Oncology, Pharmacology +17
Ken Herrmann, Margret Schottelius, Constantin Lapa et al. · Journal of Nuclear Medicine · 2015 · 269 citations · Full text